Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR(+)) advanced breast cancer. We report...

Cur síos iomlán

Sábháilte in:
Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Hope S. Rugo, Kathleen I. Pritchard, Michael Gnant, Shinzaburo Noguchi, Martine Piccart, G. N. Hortobagyi, José Baselga, Alejandra Perez, Matthias Geberth, Tibor Csőszi, E. Chouinard, Vichien Srimuninnimit, Puttisak Puttawibul, Janice F. Eakle, Wentao Feng, H. Bauly, Mona El-Hashimy, T Taran, Howard A. Burris
Formáid: Artigo
Teanga:Béarla
Foilsithe / Cruthaithe: 2014
Rochtain ar líne:https://doi.org/10.1093/annonc/mdu009
http://www.annalsofoncology.org/article/S0923753419364981/pdf
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Ar líne

https://doi.org/10.1093/annonc/mdu009
http://www.annalsofoncology.org/article/S0923753419364981/pdf

Míreanna comhchosúla